Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.

NCT06155383 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Cancer
Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Capecitabine
DRUG: oxaliplatin
DRUG: Disitamab Vedotin
DRUG: Toripalimab

Sponsor

RemeGen Co., Ltd.